TG Therapeutics, Inc.
TGTX
주식 순위
#2400
Based in New York City and established in 1993, TG Therapeutics, Inc. is a... Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
주가
$53.19
시가총액
$8.14B
변동 (1일)
-2.46%
변동 (1년)
51.02%
국가
US
거래 TG Therapeutics, Inc. (TGTX)
카테고리
Healthcare
TG Therapeutics, Inc. (TGTX)의 매출
Jun 2026 기준 매출 TTM: $799.54M
TG Therapeutics, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $799.54M입니다. 2023년에 회사는 $233.66M의 수익을 올렸으며 이는 2022년의 $2.79M 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
TG Therapeutics, Inc.의 수익 기록 (2000 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $799.54M | 143.02% |
| 2024 | $329.00M | 40.80% |
| 2023 | $233.66M | 8,290.02% |
| 2022 | $2.79M | -58.36% |
| 2021 | $6.69M | 4,300.66% |
| 2020 | $152.00K | 0.00% |
| 2019 | $152.00K | 0.00% |
| 2018 | $152.00K | -0.25% |
| 2017 | $152.38K | 0.00% |
| 2016 | $152.38K | 0.00% |
| 2015 | $152.38K | 0.00% |
| 2014 | $152.38K | 0.00% |
| 2013 | $152.38K | 699.98% |
| 2012 | $19.05K | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | -100.00% |
| 2002 | $500.00K | -81.56% |
| 2001 | $2.71M | -49.39% |
| 2000 | $5.36M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $12.62B | 1,478.95% |
US
|
|
| $2.23B | 178.66% |
US
|
|
| $15.74B | 1,869.18% |
AU
|
|
| $6.02B | 653.10% |
NL
|
|
| - | - |
CH
|
